Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamic
4.1 Introduction
4.2 Drivers
4.2.1 Rising prevalence of osteosarcoma (25%)
4.2.2 Increasing expenditure on oncology medicine and research (45%)
4.2.3 Rising demand for new treatment (30%)
4.3 Restraints
4.3.1 High cost of treatment
4.4 Technology Trends and Assessment
4.5 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Research & Product Development
5.1.2 Formulation
5.1.3 Marketing & Sales
5.1.4 Finish Products
5.2 Porter's Five Forces Model
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitutes
5.2.5 Intensity of Rivalry
5.3 Pricing Analysis
5.4 Investment opportunities
6 Global Osteosarcoma Market, By Type
6.1 Introduction
6.2 Intramedullary Osteosarcoma
6.3 Juxtacortical Osteosarcoma
6.4 Extra-Skeletal Osteosarcoma
6.5 Others
7 Global Osteosarcoma Market, By Diagnosis
7.1 Introduction
7.2 Biopsy
7.3 X-ray
7.4 Magnetic Resonance Imaging (MRI) scan
7.5 Computed Tomography (CT) Scan
7.6 Bone Scan
7.7 Others
8 Global Osteosarcoma Market, By Treatment
8.1 Introduction
8.2 Chemotherapy
8.3 Surgery
8.4 Radiation Therapy
8.5 Others
9 Global Osteosarcoma Market, By End User
9.1 Introduction
9.2 Hospital & Clinics
9.3 Cancer Research Institutes
9.4 Others
10 Global Osteosarcoma Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 U.S.
10.2.2 Canada
10.2.3 South America
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Western Europe
10.3.7 Eastern Europe
10.4 Asia Pacific
10.5 The Middle East & Africa
10.5.1 UAE
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 QATAR
10.5.6 Rest of the Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Pipeline Analysis
11.2.1 Active ingredient [6R]-5,10-methylenetetrahydrofolate:
11.2.2 Dinutuximab + Sargramostim:
11.2.3 Hu3F8 + GM-CSF:
11.3 Key Development & Strategies
12 Company Profile
12.1 Pfizer
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Products
12.1.4 Strategy
12.1.5 Key Developments
12.2 Spectrum Pharmaceuticals, Inc.
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Products
12.2.4 Strategy
12.2.5 Key Developments
12.3 Hikma Pharmaceuticals Plc
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Products
12.3.4 Strategy
12.3.5 Key Developments
12.4 Baxter
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Products
12.4.4 Strategy
12.4.5 Key Developments
12.5 ISOFOL
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Products
12.5.4 Strategy
12.5.5 Key Developments
12.6 Advaxis inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Products
12.6.4 Strategy
12.6.5 Key Developments
12.7 Bellicum Pharmaceuticals, Inc
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Products
12.7.4 Strategy
12.7.5 Key Developments
12.8 Novartis
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Products
12.8.4 Strategy
12.8.5 Key Developments
13 Conclusion
13.1 Key Findings
13.1.1 CEO's Viewpoint
13.1.2 Unmet Needs
13.1.3 Key Companies to Watch
13.1.4 Prediction of Osteosarcoma Industry
14 Appendix
14.1 Discussion Blue Print
14.2 References